

1           **Performance of Fully Automated Antimicrobial Disk Diffusion**  
2           **Susceptibility Testing Using Copan WASP Colibri coupled to**  
3           **Radian in-Line Carousel and Expert System**

4  
5  
6           **Abdessalam CHERKAOUI<sup>1</sup>, Gesuele RENZI<sup>1</sup>, Nicolas VUILLEUMIER<sup>2</sup>, and**  
7           **Jacques SCHRENZEL<sup>1,3</sup>**

8           <sup>1</sup>Bacteriology Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva  
9           University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland

10          <sup>2</sup>Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Faculty  
11          of Medicine, Geneva, Switzerland

12          <sup>3</sup>Genomic Research Laboratory, Division of Infectious Diseases, Department of Medicine, Geneva  
13          University Hospitals and Faculty of Medicine, Geneva, Switzerland

14

15  
16          **Keywords:** Automation, disk diffusion, antimicrobial susceptibility testing, COPAN  
17          WASPLab<sup>®</sup>, Colibri<sup>™</sup>, Radian<sup>™</sup>, VITEK<sup>®</sup> 2,

18

19

20

21

22          **\*Corresponding author:** Abdessalam CHERKAOUI, PhD – FAMH, Bacteriology

23          Laboratory, Division of Laboratory Medicine, Department of Diagnostics, Geneva

24          University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1205 Geneva, Switzerland

25          E-mail address: [abdessalam.cherkaoui@hcuge.ch](mailto:abdessalam.cherkaoui@hcuge.ch)

26 **Abstract**

27 The purpose of the present study was to assess the agreement at the categorical  
28 level between the VITEK<sup>®</sup> 2 system and the Colibri<sup>™</sup> coupled to the Radian<sup>™</sup> under  
29 real routine laboratory conditions. The 675 non-duplicate clinical strains included in  
30 this study (249 Enterobacterales-isolates, 198 *Pseudomonas aeruginosa*, 107  
31 *Staphylococcus aureus*, 78 coagulase-negative staphylococci, 38 *Enterococcus*  
32 *faecalis* and 5 *Enterococcus faecium*) were isolated from non-consecutive clinical  
33 samples referred to our laboratory between June and November 2020. In addition, 43  
34 carbapenemase-producing Enterobacterales (CPE) formerly identified and stored in  
35 our laboratory were added to the panel, for a total of 718 strains. The overall  
36 categorical agreements between the two compared methods were 99.3%  
37 (4350/4380; 95% CI 99% - 99.5%); 98.6% (2147/2178; 95% CI 98.0% - 99.0%);  
38 99.4% (1839/1850; 95% CI 98.9% - 99.7%); and 99.4% (342/344; 95% CI 97.9% -  
39 99.8%) for Enterobacterales, *P. aeruginosa*, *Staphylococcus* spp. and *Enterococcus*  
40 spp. respectively. The most important cause of the very major errors encountered on  
41 the VITEK<sup>®</sup> 2 for *P. aeruginosa* (62%, 13/21) was related to the presence of  
42 heteroresistant populations. Among the 43 CPE included in this study, one OXA-48-  
43 like, and one OXA-181-like were missed by the VITEK<sup>®</sup> 2, even by rigorously  
44 applying the CPE screening cut-offs defined by EUCAST. The Colibri<sup>™</sup> coupled to  
45 the Radian<sup>™</sup> provide a fully automated solution for antimicrobial disk diffusion  
46 susceptibility testing with an accuracy that is equal to or better than that of the  
47 VITEK<sup>®</sup> 2 system.

## 48 Introduction

49 One of the most important tasks of clinical bacteriology laboratories is to perform  
50 accurate antimicrobial susceptibility testing (AST) on the relevant clinical bacterial  
51 isolates. The main objective of AST consists in indicating the best antimicrobial  
52 molecules for treating the tested organism. Currently, the list of bacterial pathogens  
53 for which narrow-spectrum empirical therapy remains effective has become  
54 increasingly shorter, making AST necessary to rapidly de-escalate and target  
55 antimicrobial therapy. Since the first publications on antibiotic susceptibility testing in  
56 1954 (1), a large number of assays has been made available to assist laboratories  
57 and clinicians in selecting the appropriate antimicrobial therapy. Most commonly used  
58 testing methods encompass rapid semi-automated commercial instruments, broth  
59 microdilution, Kirby-Bauer disk diffusion, and gradient diffusion. Among them, the  
60 latter two methods provide most flexibility. Over the years, users have reported the  
61 strengths and weaknesses of each method including the list of bacteria that can be  
62 accurately tested with the ability to detect different antimicrobial resistance  
63 mechanisms (2-4). The testing methods return quantitative results expressed in MIC or  
64 provide only qualitative results (susceptible or resistant). Basically, current testing  
65 methods detect accurately the most common antimicrobial resistance mechanisms;  
66 in that sense, emerging or recently reported mechanisms warrant constant vigilance  
67 to make sure that they are correctly detected. The greatest advantage of semi-  
68 automated instrument systems compared to manual methods is that the  
69 instrumentation enables standardized reading of the end points and swift result  
70 returns because the optical systems detect tenuous changes in bacterial growth.  
71 Among the four semi-automated instruments validated by the FDA, the VITEK® 2  
72 (BioMérieux), based on repetitive turbidimetric monitoring of bacterial growth during a

73 short incubation period, is widely used in clinical microbiology laboratories around the  
74 world. The last two decades have heralded a trend away from the Kirby-Bauer disk  
75 diffusion in favor of the semi-automated testing systems. There are several reasons  
76 for this trend: (i) the accuracy of disk diffusion susceptibility testing relies on high-  
77 quality reagents (antibiotic disks and culture media), skilled laboratory procedures  
78 and correct handling of materials; and (ii) automation is only partial: several steps  
79 remain manual (e.g, media plating, distribution of antibiotic disks, reading and  
80 interpreting the inhibition zones, typing results in the laboratory information system).  
81 Overall, the disk diffusion method is time-consuming and its interpretation is more  
82 error-prone. However, the advent of full automation in microbiology laboratory should  
83 enable disk diffusion testing to become one of the major methods to deal with the  
84 emergence of new resistance mechanisms while accomodating the ever-increasing  
85 activity with a minimal workload and a high traceability.

86 To assess the performances of the fully automated antimicrobial disk diffusion  
87 susceptibility testing provided by Copan WASP Srl (Brescia, Italy), which consists of  
88 the Colibri™, the Radian™ in-Line Carousel, and the Radian™ Expert System, it is  
89 necessary to demonstrate that it provides equal or better accuracy than commonly  
90 used AST methods and that it can be applied to a broad diversity of clinically-relevant  
91 microorganisms. The overarching objective of this study was to assess the  
92 agreement at the categorical level between the VITEK® 2 system and the Colibri™  
93 coupled to the Radian™ for AST under real routine laboratory conditions. Outcome  
94 measures included the accuracy of speciation, throughput, and workflow.

95

96

97

98

**99 Materials and methods****100 Setting**

101 This study was performed in the bacteriology laboratory of Geneva University  
102 Hospitals, a Swiss tertiary care centre with more than 1'900 beds. The normal hours  
103 of operation extend from 07.30 am to 10.00 pm (7/7). About 165'000 clinical samples  
104 and 25'000 AST panels are processed annually. All AST panels are performed on the  
105 VITEK<sup>®</sup> 2 system or the SIRscan (approximately 50:50).

**106 Bacterial strains**

107 The clinical strains included in this study consisted in 675 non-duplicate strains (249  
108 Enterobacterales-isolates, 198 *Pseudomonas aeruginosa*, 107 *Staphylococcus*  
109 *aureus*, 78 coagulase-negative staphylococci, 38 *Enterococcus faecalis* and 5  
110 *Enterococcus faecium*) isolated from non-consecutive clinical samples referred to our  
111 bacteriology laboratory between June and November 2020. In addition, 43  
112 carbapenemase-producing Enterobacterales (CPE), formerly identified and stored at  
113 -80°C in skim milk with 15% glycerol, were included in the panel, for a total of 718  
114 clinical strains. All stored strains were passaged twice before testing. Table-1 depicts  
115 the Enterobacterales species and CPE included in this study. The identification of the  
116 strains was performed by matrix-assisted desorption/ionization time-of-flight mass  
117 spectrometry (Bruker Daltonics, Bremen, Germany) according to the manufacturer's  
118 instructions. The confirmation of ESBL profile was performed by double-disk synergy  
119 test (DDST20). For this test, an amoxicillin-clavulanate disk was automatically placed  
120 by Radian<sup>TM</sup> at 20 mm, center to center, of a cefepime disk on MHE agar, according  
121 to previous report (5). In the primary MHE agar plates, the amoxicillin-clavulanate  
122 disk was automatically placed by Radian<sup>TM</sup> at 27 mm, center to center, of a

123 ceftriaxone disk, and a cefepime disk (see supplementary material, Fig. S1 and Fig.  
124 S2).

125 Cefoxitin was tested systematically on all strains of the present study. We performed  
126 also the ESBL + AmpC Screen Kit 98008 (Rosco Diagnostica, Denmark) to identify  
127 the partially de-repressed AmpC whenever the results of the DDST20 and the  
128 cefoxitin were not conclusive (this is especially relevant knowing that the cefoxitin has  
129 a high sensitivity but poor specificity to identify the AmpC-producing  
130 Enterobacterales).

131 The Eazyplex<sup>®</sup> SuperBug CRE system (Amplex Biosystems GmbH, Giessen,  
132 Germany) was used to identify the various CPE. MRSA was confirmed by a  
133 previously published qPCR assay targeting *femA* and *mecA* (6).

134

### 135 **Full automation of AST by disk diffusion (Colibri<sup>™</sup>, Radian<sup>™</sup> in-Line Carousel 136 and Radian<sup>™</sup> Expert System)**

137 The Radian<sup>™</sup> is a WASPLab<sup>®</sup> module developed by Copan Wasp Srl (Brescia,  
138 Italy). It is devoted to automate AST by disk diffusion and consists of two units: i) the  
139 Radian<sup>™</sup> in-Line Carousel, which handles the media plates and dispenses the  
140 antibiotic disks. The carousel can contain up to 50 different antibiotic cartridges and  
141 enables 1 to 8 antibiotic disk deposit protocols, thereby allowing to automatically set-  
142 up the double-disk synergy test (DDST 20 mm) (see supplementary material, Fig. S1  
143 and Fig. S2); ii) the Expert System is a stand-alone software that is connected to the  
144 WASPLab<sup>®</sup> WebApp. This software allows automatic reading of inhibition zone  
145 diameters and the interpretation using EUCAST or CLSI rules. The inoculum  
146 suspension was prepared by the Colibri<sup>™</sup> in strict accordance with the  
147 manufacturer's instruction. The Colibri<sup>™</sup> prepared the inocula of 10 strains within 21

148 min. Then, that inoculum (2 x 30 µl loop/spreader) was streaked by the WASP<sup>®</sup> over  
149 the entire surface of round Mueller-Hinton agar plates (MHE) (BioMérieux, Geneva,  
150 Switzerland) according to the AST streaking pattern defined by Copan, which was  
151 previously tested and validated in our previous report (7). The antibiotic disks are  
152 then dispensed by the Radian<sup>™</sup> in-Line Carousel and the inoculated media  
153 transferred by conveyors to the automated incubators (Figure-1).

154 All the antibiotic cartridges are always stored at 4°C according to the manufacturer's  
155 instructions. The antibiotic cartridges were installed in the Radian<sup>™</sup> carousel only  
156 when performing the AST. WASP<sup>®</sup> plus Radian<sup>™</sup> in-Line Carousel executed AST for  
157 10 strains (i.e. 40 media plates with 200 distributed antibiotic disks) within 44 min.  
158 Plates were incubated for 16 h on the WASPLab<sup>®</sup>, and several high-resolution digital  
159 images were acquired under different light and exposure conditions according to the  
160 manufacturer's instructions. Inhibition zone diameters were automatically read by the  
161 WASPLab<sup>®</sup>. The inhibition zone diameters were adjusted manually when deemed  
162 necessary, which represents less than 10% of the tested disks. All digital images and  
163 the final AST results were validated on the WASPLab<sup>®</sup> screen by microbiologists and  
164 experienced technologists without any automatic release of the AST results by the  
165 WASPLab<sup>®</sup>.

166 The AST interpretation was performed by the Radian<sup>™</sup> Expert System according to  
167 the EUCAST breakpoints, version 9.0. In this study, we used the i2a antibiotic disks  
168 (i2a, Montpellier, France).

169

### 170 **VITEK<sup>®</sup> 2 susceptibility testing**

171 The AST on the VITEK<sup>®</sup> 2 system were performed in strict accordance with the  
172 manufacturer's instruction, as part of routine procedures in our accredited

173 bacteriology laboratory. The EUCAST breakpoints, version 9.0, were applied by the  
174 VITEK<sup>®</sup> 2 system. The inoculum suspension was prepared manually by picking a  
175 sufficient number of morphologically similar colonies from overnight growth with a  
176 sterile stick and by suspending the colonies in sterile saline (aqueous 0.45% to 0.5%  
177 NaCl, pH 4.5 to 7.0) to an appropriate McFarland standard using the  
178 DensiCHEK<sup>™</sup> Plus. Purity check plate were performed for all the analyzed strains to  
179 ensure that a pure culture was used. We used the following AST cards, AST-N290,  
180 AST-N240, AST-P636, and AST-P655 (BioMérieux, Geneva, Switzerland).

181

#### 182 **Internal quality controls**

183 Eight independent biological replicates of *Staphylococcus aureus* ATCC 29213,  
184 *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, and  
185 *Enterococcus faecalis* ATCC 29212 were used as internal quality controls to assess  
186 the accuracy, reproducibility and repeatability of the fully automated AST method and  
187 of the VITEK<sup>®</sup> 2 system. We assessed also the stability of the antibiotic disks in the  
188 Radian<sup>™</sup> in-Line carousel. To that purpose, we performed AST at different time  
189 points (15min, 2h, 4h, 5h, 6h, 8h, 10h, and 11h30) corresponding to the time elapsed  
190 after loading the antibiotic cartridges on the Radian<sup>™</sup> carousel.

191

#### 192 **Discordant results**

193 The fully automated AST results were compared to the VITEK<sup>®</sup> 2 results, the latter  
194 being routinely performed in our laboratory. When both methods agreed, we  
195 considered the susceptibility category as correct and no further determination was  
196 attempted. When the methods gave discordant testing results, we systematically  
197 performed broth microdilution (Thermo Scientific<sup>™</sup> Sensititre<sup>™</sup> MIC plate, USA) to



198 resolve the uncertainty. The discordant results were scored as ‘very major error’ if  
199 reported susceptible by the fully automated AST or the VITEK<sup>®</sup> 2 but resistant by  
200 broth microdilution and as ‘major error’ if resistant by the fully automated AST or the  
201 VITEK<sup>®</sup> 2 but deemed susceptible by broth microdilution.

202 Additionally, when the discordant results were related to antimicrobial  
203 heteroresistance population (colonies visible within the inhibition halo of the disk  
204 diffusion), we assessed the resistant subpopulations in heteroresistant strains by E-  
205 test strips since various reports have stressed that heteroresistance is accurately  
206 detected by this method (8-12).

207

## 208 **Results**

### 209 **Enterobacterales**

210 Among the 292 Enterobacterales strains tested, 30 discordant results were observed  
211 at the categorical level; the overall categorical agreement between the compared  
212 methods was 99.3% (4350/4380; 95% CI 99% - 99.5%). No discordant results at the  
213 categorical level were observed for ampicillin, cefuroxime and norfloxacin. Fifteen  
214 major errors were observed on the Copan’s full automation AST. In contrast, twelve  
215 very major errors and three major errors were observed on the VITEK<sup>®</sup> 2 (Table 2).  
216 Importantly, a strict application of the screening cut-off values for carbapenemase-  
217 producing Enterobacterales (CPE) according to EUCAST methodology, which  
218 consists in the use of meropenem (best balance of sensitivity and specificity /  
219 screening cut-off : MIC >0.125 mg/l or inhibition zone diameter <28 mm) (13),  
220 enabled the detection of all 43 CPE included in this study by the Copan’s full  
221 automated AST. The lowest value of MIC determined by the VITEK<sup>®</sup> 2 for  
222 meropenem is ≤0.25 mg/l, which does not permit using the CPE screening cut-  
223 off defined by EUCAST, and limiting therefore the possibilities to suspect the

224 presence of CPE. As depicted in the Supplementary material, Table S1, one strain  
225 producing OXA-181-like and another strain with OXA-48-like were missed by the  
226 VITEK<sup>®</sup> 2 because their MICs for meropenem and ertapenem were  $\leq 0.25$  mg/l and  
227  $\leq 0.5$  mg/l, respectively. Two other strains producing OXA-181-like had meropenem  
228 MICs of 1 and 2 mg/l. By rigorously applying the EUCAST CPE screening cut-offs,  
229 these two strains were therefore suspected and then confirmed as CPE by using  
230 molecular assays. Obviously, all these four CPE strains were easily suspected as  
231 CPE by the Copan's fully automated AST because ertapenem was reported as  
232 resistant and the meropenem inhibition zone diameter was  $< 28$  mm (see  
233 supplementary material, Table S1).

234

### 235 ***Pseudomonas aeruginosa***

236 Among the 198 *Pseudomonas aeruginosa* analyzed, we observed 31 discordant  
237 results at the categorical level. The overall categorical agreement between the  
238 compared methods was 98.6% (2147/2178; 95% CI 98.0%-99.0%). Two very major  
239 errors and two major errors were observed on the Copan's fully automated AST.  
240 Twenty-one very major errors and six major errors were observed on the VITEK<sup>®</sup> 2  
241 (Table 2). Among the 21 very major errors recorded on the VITEK<sup>®</sup> 2, 62% (13/21)  
242 were linked to heteroresistance profiles that are typically missed by the VITEK<sup>®</sup> 2. In  
243 contrast, colonies inside the inhibition halo of the antibiotic disk diffusion were  
244 observed for all such strains, indicating the presence of heteroresistant populations  
245 (Figure-1, bottom left, and Supplementary material, Fig. S3). The identification of all  
246 the colonies visible within the inhibition halo was confirmed by MALDI-TOF MS to  
247 exclude any contamination.

248

### 249 ***Staphylococcus spp.***

250 No discordant results at the categorical level were observed for cefoxitin, gentamicin,  
251 clindamycin, erythromycin, fusidic acid, rifampicin, linezolid, and tigecycline. Two  
252 major errors were observed on the Copan's fully automated AST for ciprofloxacin (*S.*  
253 *aureus*) and co-trimoxazole (*S. epidermidis*). However, ten very major errors were  
254 identified on the VITEK<sup>®</sup> 2 for co-trimoxazole according to broth microdilution results.  
255 These very major errors were reported only for Coagulase-negative staphylococci (1  
256 *S. hominis* and 9 *S. epidermidis*) (see supplementary material, Fig. S4). The  
257 categorical agreement for *S. aureus* strains was 99.9% (1069/1070; 95% CI 99.5%-  
258 100%). The overall categorical agreement between the two compared methods for all  
259 the 185 *Staphylococcus* spp. strains yielded to 99.4% (1839/1850; 95% CI 98.9%-  
260 99.7%).

261

#### 262 ***Enterococcus* spp.**

263 No discordant results at the categorical level were observed for gentamicin, linezolid,  
264 teicoplanin, vancomycin, nitrofurantoin, and tigecycline. One major error was  
265 observed on the Copan's fully automated AST for ampicillin, and one very major error  
266 on the VITEK<sup>®</sup> 2 for imipenem. Hence, the overall categorical agreement between  
267 the two compared methods for *Enterococcus* spp. strains yielded to 99.4% (342/344;  
268 95% CI 97.9%-99.8%).

269

#### 270 **Internal quality controls**

271 Cautious analysis was paid to assess the stability of the antibiotic disks in the  
272 Radian<sup>™</sup> in-Line carousel. AST on the Copan's full automation were carried out at  
273 specific time points after antibiotic cartridges were loaded on the Radian<sup>™</sup> carousel.  
274 We made sure that these time points match the hours of operation in our laboratory.  
275 For the eight independent biological replicates of *Staphylococcus aureus* ATCC

276 29213, *Escherichia coli* ATCC 25922, *Pseudomonas aeruginosa* ATCC 27853, and  
277 *Enterococcus faecalis* ATCC 29212, the inhibition zone diameters were always in the  
278 range defined by EUCAST for all the antibiotic disks and at all the different time  
279 points assessed (see supplementary material, Fig. S5).

280 No problem was observed for the internal quality controls on the VITEK<sup>®</sup> 2 system.

281

## 282 Discussion

283 For many years, there has been only few improvements in the disk diffusion AST.

284 Even with the advent of semi-automatic readers such as SIRscan 2000 Automatic  
285 (i2a, Montpellier, France), Adagio (Bio-Rad, USA) or BIOMIC V3 (Giles Scientific,  
286 USA) instruments, the manual set-up of the disk diffusion and the availability of  
287 several automated liquid-based systems for performing AST (VITEK<sup>®</sup>, Phoenix<sup>®</sup>,  
288 MicroScan) have thwarted its large scale-use in clinical microbiology laboratories.

289 However, there has been a resurgence of interest lately in disk diffusion because this  
290 method offers a large degree of flexibility, efficiency, reliability, and cost effectiveness  
291 that enables extended and customized susceptibility testing, especially when facing  
292 the emergence of new resistance mechanisms. This is also supported by the poor  
293 performance of automated liquid-based systems to detect some carbapenemases  
294 (e.g. OXA-48-like, OXA-181-like) and the heteroresistance profiles. The advent of a  
295 full automation in clinical microbiology laboratory has revolutionized the process. In  
296 essence, several incentives have driven the advent of the full automation: i)  
297 increased processing capacity, ii) standardization of the process, which enables  
298 better costs control, iii) optimized traceability, iv) improved workflows, and v) reduced  
299 turnaround times. Different reports have shown that most of these expectations  
300 were achieved (14-18). Despite the increasing interest for disk diffusion AST, the lack

301 of automation has prevented many microbiology laboratories to use this method.  
302 Nowadays, a fully integrated and automated system for AST by disk diffusion is  
303 available. It allows: i) to prepare an inoculum suspension by the Colibri™, ii) to  
304 inoculate this suspension over the entire surface of Mueller-Hinton agar plates by the  
305 WASP®, iii) to automatically dispense antibiotic disks from a selection of up to 50  
306 antibiotic loaded on the Radian™ in-Line Carousel , iv) to automatically incubate the  
307 media plates on the WASPLab®, v) to image the media plates at specified time  
308 points, and vi) to extract and interpret inhibition zones diameters by the  
309 Radian™Expert System based on EUCAST or CLSI breakpoints. In order to evaluate  
310 the accuracy of the fully automated disk diffusion AST provided by Copan, it was  
311 important to examine a representative number of clinical strains that are resistant to  
312 various antibiotic molecules, to assess the ability of this method to detect various  
313 resistance mechanisms, and to define the rate of major errors by assessing a  
314 significant number of susceptible strains. The overall categorical agreement between  
315 the VITEK® 2 system and the Colibri™ coupled to Radian™ for the 718 non-duplicate  
316 clinical strains analyzed in the present study reached 99.1% (8548/8752; 95% CI  
317 98.9% - 99.3%). The most important cause of very major errors encountered on the  
318 VITEK® 2 for *P. aeruginosa* was related to the presence of heteroresistant  
319 populations. This finding has been previously highlighted in various reports (10, 12,  
320 19). Heteroresistance constitutes a relevant cause of treatment failure, especially in  
321 recurrent or chronic infections. Thus, the risk of treatment failure is increased if the  
322 presence of a highly resistant subpopulation is not considered when prescribing  
323 antibiotics (10, 20-22). The rising global incidence of CPE constitutes a compelling  
324 challenge to public health because they are causing worse clinical outcomes. OXA-  
325 48-like carbapenemases belong to the Ambler class D  $\beta$ -lactamases. OXA-48-like

326 has been reported in different Enterobacterales species and its transmission between  
327 species via plasmids is now clearly established (23). The OXA-48-like family is widely  
328 disseminated and constitutes a significant proportion of reported carbapenemases in  
329 different countries. However, OXA-48-like producers may be missed by some routine  
330 AST methods, due in part to their relative susceptibility to carbapenems and  
331 cephalosporins (23). Among the 43 CPE included in this study, one OXA-48-like, and  
332 one OXA-181-like were missed by the VITEK<sup>®</sup> 2, even by rigorously applying the  
333 CPE screening cut-off defined by EUCAST. Other hallmarks of the phenotypic AST  
334 methods compared in the present study are summarized in Table-3. Another issue  
335 was encountered with co-trimoxazole and Coagulase-negative staphylococci on the  
336 VITEK<sup>®</sup> 2. This is a matter of concern that implies thorough and precautionary  
337 analysis. The Radian<sup>™</sup> is not equipped with a cooling device, which highlights the  
338 importance of running internal quality controls using ATCC strains to assess the  
339 stability of the antibiotic disks. Our analysis of the internal quality controls using  
340 ATCC strains showed that the antibiotic disks were stable after loading the Radian<sup>™</sup>  
341 carousel for at least 11h30, permitting a smooth management of the antibiotic  
342 cartridges. Finally, the fully automated solution for antimicrobial disk diffusion  
343 susceptibility enables to respect the EUCAST rule of 15-15-15 for the AST  
344 procedure.

345 All testing results are reported as percent agreement at the categorical level between  
346 the VITEK<sup>®</sup> 2 system and the Colibri<sup>™</sup> coupled to Radian<sup>™</sup> under real routine  
347 laboratory conditions. The use of the percent agreement statistic may have some  
348 limitations, when considering a small number of determinations.

349

350

351

352

353

354

355

**356 Conclusions**

357 It has been pointed out that the workload requirements for Kirby-Bauer disk diffusion  
358 hindered its routine implementation in many clinical microbiology laboratories.  
359 However, the fully automated solution for antimicrobial disk diffusion provided by  
360 Copan will address these constraints with an accuracy that is equal to or better than  
361 that of the VITEK<sup>®</sup> 2 system. By implementing the automation process in a stepwise  
362 manner (IT development, validation of the performances, staff training, and then  
363 routine implementation) we have become able to process 80% of our routine AST  
364 panels using the Colibri<sup>™</sup> coupled to the Radian<sup>™</sup> within two months.

365 In addition, this fully automated solution will facilitate the implementation of the  
366 EUCAST rapid AST directly from positive blood-culture bottles. Further studies are  
367 now needed to validate the EUCAST rapid AST using the Colibri<sup>™</sup> coupled to the  
368 Radian<sup>™</sup>, and to investigate the real impact of this protocol on the early adjustments  
369 of the antimicrobial regimen. Finally, the emergence of new antimicrobial resistance  
370 mechanisms, including some that may be difficult to detect like carbapenemase  
371 production, implies that the analytical performances of the diagnostic devices should  
372 be iteratively reassessed and regularly challenged with internal and external quality  
373 controls to swiftly detect systematic errors.

374

375

376

377



378 **Funding**

379 This study was performed by using internal funding.

380

381 **Conflict of Interest Statement**

382 The authors declare that the research was conducted in the absence of any  
383 commercial or financial relationships that could be construed as a potential conflict of  
384 interest.

385

386 **Ethical approval**

387 In accordance with local ethical committee, routine clinical laboratories of our  
388 institution may use biological sample leftovers for method development after  
389 irreversible anonymization of data. The official name of the ethics committee is  
390 "Commission cantonale d'éthique de la recherche (CCER)" [https://www.hug-  
391 ge.ch/ethique](https://www.hug-ge.ch/ethique)

392

393 **Acknowledgments**


394 The authors would like to thank Didier SCHORDERET, Nouria AZAM, Lara RASGA,  
395 Luigi CRUDELI, Stephane EMONET, Ruwag and Copan teams for technical  
396 assistance.


397 **References**

398

- 399 1. Hutchison JG. 1954. Antibiotic sensitivity tests: a rapid method suitable for multiple cultures.  
400 J Clin Pathol 7:350-1.
- 401 2. Johnson JE, Jorgensen JH, Crawford SA, Redding JS, Pruneda RC. 1983. Comparison of two  
402 automated instrument systems for rapid susceptibility testing of gram-negative bacilli. J Clin  
403 Microbiol 18:1301-9.
- 404 3. Joyanes P, del Carmen Conejo M, Martinez-Martinez L, Perea EJ. 2001. Evaluation of the  
405 VITEK 2 system for the identification and susceptibility testing of three species of  
406 nonfermenting gram-negative rods frequently isolated from clinical samples. J Clin Microbiol  
407 39:3247-53.
- 408 4. Nonhoff C, Rottiers S, Struelens MJ. 2005. Evaluation of the Vitek 2 system for identification  
409 and antimicrobial susceptibility testing of *Staphylococcus* spp. Clin Microbiol Infect 11:150-3.
- 410 5. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. 2011. Comparison of nine  
411 phenotypic methods for detection of extended-spectrum beta-lactamase production by  
412 Enterobacteriaceae. J Clin Microbiol 49:1048-57.
- 413 6. Francois P, Pittet D, Bento M, Pepey B, Vaudaux P, Lew D, Schrenzel J. 2003. Rapid detection  
414 of methicillin-resistant *Staphylococcus aureus* directly from sterile or nonsterile clinical  
415 samples by a new molecular assay. J Clin Microbiol 41:254-60.
- 416 7. Cherkaoui A, Renzi G, Fischer A, Azam N, Schorderet D, Vuilleumier N, Schrenzel J. 2020.  
417 Comparison of the Copan WASPLab incorporating the BioRad expert system against the  
418 SIRscan 2000 automatic for routine antimicrobial disc diffusion susceptibility testing. Clin  
419 Microbiol Infect 26:619-625.
- 420 8. Cherkaoui A, Diene SM, Renzoni A, Emonet S, Renzi G, Francois P, Schrenzel J. 2017.  
421 Imipenem heteroresistance in nontypeable *Haemophilus influenzae* is linked to a  
422 combination of altered PBP3, slow drug influx and direct efflux regulation. Clin Microbiol  
423 Infect 23:118 e9-118 e19.
- 424 9. Hung KH, Wang MC, Huang AH, Yan JJ, Wu JJ. 2012. Heteroresistance to cephalosporins and  
425 penicillins in *Acinetobacter baumannii*. J Clin Microbiol 50:721-6.
- 426 10. He J, Jia X, Yang S, Xu X, Sun K, Li C, Yang T, Zhang L. 2018. Heteroresistance to carbapenems  
427 in invasive *Pseudomonas aeruginosa* infections. Int J Antimicrob Agents 51:413-421.
- 428 11. Ikonomidis A, Neou E, Gogou V, Vrioni G, Tsakris A, Pournaras S. 2009. Heteroresistance to  
429 meropenem in carbapenem-susceptible *Acinetobacter baumannii*. J Clin Microbiol 47:4055-9.
- 430 12. Jia X, Ma W, He J, Tian X, Liu H, Zou H, Cheng S. 2020. Heteroresistance to cefepime in  
431 *Pseudomonas aeruginosa* bacteraemia. Int J Antimicrob Agents 55:105832.
- 432 13. Anonymous. July 2017. EUCAST guidelines for detection of resistance mechanisms and  
433 specific resistances of clinical and/or epidemiological importance. Version 2.0.
- 434 14. Cherkaoui A, Renzi G, Charretier Y, Blanc DS, Vuilleumier N, Schrenzel J. 2019. Automated  
435 Incubation and Digital Image Analysis of Chromogenic Media Using Copan WASPLab Enables  
436 Rapid Detection of Vancomycin-Resistant Enterococcus. Front Cell Infect Microbiol 9:379.
- 437 15. Cherkaoui A, Renzi G, Vuilleumier N, Schrenzel J. 2019. Copan WASPLab automation  
438 significantly reduces incubation times and allows earlier culture readings. Clin Microbiol  
439 Infect 25:1430 e5-1430 e12.
- 440 16. Cherkaoui A, Renzi G, Azam N, Schorderet D, Vuilleumier N, Schrenzel J. 2020. Rapid  
441 identification by MALDI-TOF/MS and antimicrobial disk diffusion susceptibility testing for  
442 positive blood cultures after a short incubation on the WASPLab. Eur J Clin Microbiol Infect  
443 Dis 39:1063-1070.
- 444 17. Cherkaoui A, Renzi G, Martischang R, Harbarth S, Vuilleumier N, Schrenzel J. 2020. Impact of  
445 Total Laboratory Automation on Turnaround Times for Urine Cultures and Screening

- 446 Specimens for MRSA, ESBL, and VRE Carriage: Retrospective Comparison With Manual  
447 Workflow. *Front Cell Infect Microbiol* 10:552122.
- 448 18. Cherkaoui A, Renzi G, Viollet A, Fleischmann M, Metral-Boffod L, Dominguez-Amado D,  
449 Vuilleumier N, Schrenzel J. 2020. Implementation of the WASPLab and first year  
450 achievements within a university hospital. *Eur J Clin Microbiol Infect Dis* 39:1527-1534.
- 451 19. Frebourg NB, Nouet D, Lemee L, Martin E, Lemeland JF. 1998. Comparison of ATB staph,  
452 rapid ATB staph, Vitek, and E-test methods for detection of oxacillin heteroresistance in  
453 staphylococci possessing *mecA*. *J Clin Microbiol* 36:52-7.
- 454 20. Mei S, Gao Y, Zhu C, Dong C, Chen Y. 2015. Research of the heteroresistance of *Pseudomonas*  
455 *aeruginosa* to imipenem. *Int J Clin Exp Med* 8:6129-32.
- 456 21. Pournaras S, Ikonomidis A, Markogiannakis A, Spanakis N, Maniatis AN, Tsakris A. 2007.  
457 Characterization of clinical isolates of *Pseudomonas aeruginosa* heterogeneously resistant to  
458 carbapenems. *J Med Microbiol* 56:66-70.
- 459 22. Pournaras S, Kristo I, Vrioni G, Ikonomidis A, Poulou A, Petropoulou D, Tsakris A. 2010.  
460 Characteristics of meropenem heteroresistance in *Klebsiella pneumoniae* carbapenemase  
461 (KPC)-producing clinical isolates of *K. pneumoniae*. *J Clin Microbiol* 48:2601-4.
- 462 23. Pitout JDD, Peirano G, Kock MM, Strydom KA, Matsumura Y. 2019. The Global Ascendency of  
463 OXA-48-Type Carbapenemases. *Clin Microbiol Rev* 33.
- 464





**Figure-1 (Parts 1 to 6):** Workflow of a fully automated solution for antimicrobial disk diffusion susceptibility testing (Colibri™, WASP™, Radian™ in-Line Carousel, and Radian™ Expert System)

Colibri™ prepares the inocula for 10 strains within 21 min

AST Line (WASP™ + Radian™ in Line Carousel) executes AST for 10 strains (i.e. 40 media plates and 200 antibiotic discs) within 44 min

Species	Number of strains	ESBL	NDM-producers	KPC-producers	OXA-48-like producers	OXA-181-like producers
<i>Escherichia coli</i>	190	16	1	1	4	7
<i>Klebsiella pneumoniae</i>	51	16	3	2	7	6
<i>Klebsiella oxytoca</i>	3					
<i>Klebsiella aerogenes</i>	2					
<i>Proteus mirabilis</i>	20	2	2			
<i>Proteus vulgaris</i>	1					
<i>Citrobacter koseri</i>	4	4				4
<i>Citrobacter freundii</i> complex	7	3			3	
<i>Serratia marcescens</i>	1					
<i>Enterobacter cloacae</i> complex	7	2	1		1	
<i>Hafnia alvei</i>	2	1			1	
<i>Providencia rettgeri</i>	2					
<i>Morganella morganii</i>	2					
<b>Total</b>	<b>292</b>	<b>44</b>	<b>7</b>	<b>3</b>	<b>16</b>	<b>17</b>

**Table-1** : Enterobacterales strains included in this study  
ESBL : Extended spectrum  $\beta$ -lactamases

Antibiotics	Resistance rate % (no. of isolates)	Categorical agreement between the compared methods (%)	Colibri™ coupled to Radian™		VITEK 2® system	
			Very major error	Major error	Very major error	Major error
<b>Enterobacterales species (n=292)</b>						
Ampicillin	66 (193)	100				
Amoxicillin/Clavulanate	37 (108)	99.7		1		
Piperacillin/Tazobactam	21 (62)	98.6		2	2	
Cefuroxime	25 (73)	100				
Ceftazidime	22 (63)	99.3		2		
Ceftriaxone	22 (63)	99.3		2		
Cefepime	19 (56)	99		1	3	
Imipenem	6 (18)	98.6		2	1	1
Meropenem	7 (19)	99.7			1	
Ertapenem	17 (49)	97.6		3	4	
Amikacin	7 (19)	99.7			1	
Gentamicin	15 (45)	99.7		1		
Norfloxacin	35 (101)	100				
Ciprofloxacin	29 (85)	99.3				2
Co-trimoxazole	35 (103)	99.7		1		
<b><i>Pseudomonas aeruginosa</i> (n=198)</b>						
Piperacillin	43 (85)	94	1		11 (incl. 5*)	
Piperacillin/Tazobactam	33 (65)	98.5			1	2
Ceftazidime	28 (56)	99.5		1		
Cefepime	28 (55)	99		1	1*	
Imipenem	30 (60)	98.5	1		2*	
Meropenem	27 (53)	98			4*	
Amikacin	24 (47)	99.5				1
Gentamicin	21 (42)	99				2
Tobramycin	23 (46)	100				
Ciprofloxacin	25 (49)	99.5				1
Levofloxacin	31 (61)	99			2 (incl. 1*)	
*Presence of colonies within the inhibition halo (heteroresistance detected only by disk diffusion)						
<b><i>Staphylococcus</i> spp. (n=185 including 107 <i>Staphylococcus aureus</i> and 78 Coagulase-negative staphylococci )</b>						
Cefoxitine	32 (60)	100				
Gentamicin	21 (39)	100				
Ciprofloxacin	32 (60)	99.5			1	
Clindamycin	29 (53)	100				
Erythromycin	34 (62)	100				
Fusidic acid	26 (48)	100				
Co-trimoxazole	23 (42)	94.6			10	
Rifampicin	3 (6)	100				
Tigecyclin	0	100				
Linezolid	0	100				
<b><i>Enterococcus</i> spp. (n=43 including 38 <i>Enterococcus faecalis</i> and 5 <i>Enterococcus faecium</i> )</b>						
Ampicillin	9 (4)	97.7		1		
Imipenem	9 (4)	97.7			1	
Gentamicin	9* (4)	100				
Linezolid	0	100				
Teicoplanin	0	100				
Vancomycin	0	100				
Tigecycline	0	100				
Nitrofurantoin	0**	100				

\*High level of gentamicin resistance / \*\*only *Enterococcus faecalis* isolates were included

**Table-2** : Prevalence (%) of antibiotic resistance phenotypes in the 718 clinical isolates included in this study and categorical agreement between the compared methods

Colibri™ coupled to Radian™	VITEK® 2 system
<ul style="list-style-type: none"> <li>• Fully automated method</li> <li>• Easy to change the antibiotics tested</li> <li>• Greatest flexibility and cost-effectiveness</li> <li>• Reliable for detecting heteroresistant subpopulations</li> <li>• Easy to see test failures (e.g., mixed inoculum)</li> <li>• More accurate detection of new resistance mechanisms</li> <li>• Applicable to many fastidious organisms</li> <li>• Inability to provide precise data regarding the level of an organism's resistance or susceptibility</li> </ul>	<ul style="list-style-type: none"> <li>• Semi automated method</li> <li>• Less flexible and more expensive (susceptibility cards)</li> <li>• Low sensitivity for the detection of heteroresistant subpopulations</li> <li>• Purity check plates are mandatory (more consumable and additional workload)</li> <li>• Problems in detecting some patterns of carbapenemases (e.g., OXA-48-like producers)</li> <li>• The range of drug dilution is usually very narrow</li> <li>• Provide a good approximation of the MIC</li> </ul>

**Table -3** : Hallmarks of the phenotypic AST methods compared in this study